期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
康柏西普治疗糖尿病患者白内障术后不同类型黄斑水肿的疗效 被引量:11
1
作者 郑华宾 宫月荣 +2 位作者 曹晓宁 李卫国 张培培 《国际眼科杂志》 CAS 北大核心 2020年第11期1967-1970,共4页
目的:观察康柏西普治疗糖尿病患者白内障术后不同类型黄斑水肿的疗效。方法:选取2017-01/2018-12于我院行白内障超声乳化联合人工晶状体植入术后视力再次下降并确诊为黄斑水肿的糖尿病患者52例52眼。根据黄斑水肿OCT分型,将发生弥漫性... 目的:观察康柏西普治疗糖尿病患者白内障术后不同类型黄斑水肿的疗效。方法:选取2017-01/2018-12于我院行白内障超声乳化联合人工晶状体植入术后视力再次下降并确诊为黄斑水肿的糖尿病患者52例52眼。根据黄斑水肿OCT分型,将发生弥漫性黄斑水肿者18眼纳入DRT组,发生黄斑囊样水肿者20眼纳入CME组,发生浆液性视网膜脱离者14眼纳入SRD组,均按照1+PRN方案行玻璃体腔注射康柏西普。治疗(首次玻璃体腔注射)后随访12mo,观察并比较各组患者最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT),并记录药物注射次数。结果:三组患者治疗前BCVA和CMT无明显差异,但DRT组黄斑水肿发病时间明显短于CME组和SRD组(P<0.05)。治疗后1mo,三组患者BCVA和CMT均明显好转,且治疗后3mo起,三组患者BCVA和CMT继续好转并逐渐稳定,与治疗前比较均明显改善(P<0.05)。治疗后1、3、6、12mo,DRT组和CME组患者BCVA和CMT均好于SRD组(P<0.05),但DRT组与CME组之间无明显差异(均P>0.05)。三组患者药物注射次数分别为3.2±0.9、2.9±0.8、4.1±1.1次,SRD组注射次数明显多于DRT组和CME组(均P<0.05)。结论:糖尿病患者白内障术后黄斑水肿应早期干预,康柏西普可以有效改善白内障术后不同类型黄斑水肿患者的视力,减轻黄斑水肿。 展开更多
关键词 康柏西普 糖尿病 白内障 黄斑水肿 玻璃体腔注射
下载PDF
玻璃体切割联合内界膜覆盖术治疗高度近视黄斑裂孔视网膜脱离 被引量:3
2
作者 郑华宾 韩彦辉 +3 位作者 孟繁超 李丽 孟东方 王东林 《国际眼科杂志》 CAS 北大核心 2022年第12期2087-2090,共4页
目的:比较玻璃体切割联合内界膜剥除术或内界膜覆盖术治疗高度近视黄斑裂孔视网膜脱离(MHRD)的疗效。方法:回顾性临床研究。选取2020-01/2021-06于我院行玻璃体切割联合内界膜剥除术或内界膜覆盖术治疗的高度近视MHRD患者38例38眼,根据... 目的:比较玻璃体切割联合内界膜剥除术或内界膜覆盖术治疗高度近视黄斑裂孔视网膜脱离(MHRD)的疗效。方法:回顾性临床研究。选取2020-01/2021-06于我院行玻璃体切割联合内界膜剥除术或内界膜覆盖术治疗的高度近视MHRD患者38例38眼,根据手术方式分为对照组(行玻璃体切割联合内界膜剥除术)和观察组(行玻璃体切割联合内界膜覆盖术)。随访至术后3mo,比较两组患者手术时间、最佳矫正视力(BCVA)、黄斑裂孔闭合和视网膜复位情况。结果:两组患者手术时间无差异(30.71±4.55min vs 35.20±5.44min,P=0.384)。末次随访时,两组患者BCVA均较术前明显改善(均P<0.01),但两组患者BCVA(LogMAR)无差异(1.39±0.24 vs 1.46±0.27,P=0.700);观察组患者黄斑裂孔闭合率高于对照组(100%vs 71%,P=0.024),但两组患者视网膜再脱离率比较无差异(0 vs 10%,P=0.492)。结论:两种手术方式均可改善患者视力,但玻璃体切割联合内界膜覆盖术后黄斑裂孔闭合率更高。 展开更多
关键词 高度近视 黄斑裂孔视网膜脱离 玻璃体切割 内界膜覆盖 内界膜剥除
下载PDF
Electroacupuncture for the prevention of postoperative gastrointestinal dysfunction in patients undergoing vascular surgery under general anesthesia: study protocol for a prospective practical randomized controlled trial 被引量:20
3
作者 Ying Li Hui zheng +10 位作者 Qian-hua zheng Ling Zhao Er-qi Qin Yu Wang Qian Zeng hua-bin zheng Yu Zhao Wei Sun Xiao-xia Zhang Zhi-shun Liu Bao-yan Liu 《Journal of Integrative Medicine》 SCIE CAS CSCD 2014年第6期512-519,共8页
BACKGROUND: Postoperative gastrointestinal dysfunction(PGD) is one of the most common complications following major surgeries under general anesthesia(GA). Despite ongoing research and new drug treatments, abdomi... BACKGROUND: Postoperative gastrointestinal dysfunction(PGD) is one of the most common complications following major surgeries under general anesthesia(GA). Despite ongoing research and new drug treatments, abdominal distension within 24 h postoperatively occurs in 8%–28% of all surgeries. We aim to analyze the effectiveness of preventing PGD by preoperatively stimulating Neiguan(PC6), Zusanli(ST36) and Shangjuxu(ST37) bilaterally twice a day compared with sham-acupuncture treatment and standard treatment.METHODS AND DESIGN: This is a single-center, prospective practical randomized controlled trial. All groups will be given standard treatments. Patients undergoing vascular surgery under GA will be included from the Vascular Surgery Unit in West China Hospital of Sichuan University, China, and divided into three groups. The experimental group will receive routine treatments and acupuncture at PC6, ST36 and ST37 bilaterally with electrical stimulation twice a day for 20 min preoperatively. The sham-acupuncture group will receive pseudo-electroacupuncture at sham acupoints of PC6, ST36 and ST37, which are 1 cun away from the real acupoints. The routine-treatment group will not receive electroacupuncture. The outcomes include the incidence of abdominal distention, abdominal circumference, the degree of abdominal distension, the fi rst time of fl atus and defecation, and hospitalization duration. DISCUSSION: The results from this study will demonstrate whether preoperative electroacupuncture is an effective method for the prevention of PGD in patients undergoing vascular surgery under GA. This study may also provide a standardized acupuncture treatment for reduction of PGD. TRIAL REGISTRATION: This study is registered with the Chinese Clinical Trial Registry: Chi CTR-TRC-13003649. 展开更多
关键词 electroacupuncture gastrointestinal dysfunction vascular surgery study protocol
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部